Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Leukemia, Myeloid, Acute 246Precursor Cell Lymphoblastic Leukemia-Lymphoma 147Myelodysplastic Syndromes 144Leukemia, Lymphocytic, Chronic, B-Cell 140Leukemia 128Multiple Myeloma 118Lymphoma 116Lymphoma, Non-Hodgkin 112Recurrence 80Hematologic Neoplasms 77Melanoma 68Hodgkin Disease 68Leukemia, Myelogenous, Chronic, BCR-ABL Positive 67Lymphoma, B-Cell 61Lymphoma, Mantle-Cell 52Lymphoma, Large B-Cell, Diffuse 50Lymphoma, Follicular 50Burkitt Lymphoma 41Ovarian Neoplasms 40Neoplasms 39Myeloproliferative Disorders 39Neoplasm Metastasis 34Lymphoma, B-Cell, Marginal Zone 30Graft vs Host Disease 29Neoplasms, Plasma Cell 28Carcinoma, Non-Small-Cell Lung 27Breast Neoplasms 27Leukemia, Biphenotypic, Acute 25Primary Myelofibrosis 24Anemia, Refractory, with Excess of Blasts 23

Interventions

ganglioside, GD2 1fludarabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gaucher Disease × fludarabine × Clear all
NCT03721068 2026-03-27

Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

UNC Lineberger Comprehensive Cancer Center

Phase 1 Recruiting
18 enrolled
CNSSarcoma

Gaucher Disease, Neuroblastoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡